Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Prostatic Neoplasms

Adenocarcinoma

Neoplasm Metastasis

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Bone Density Conservation Agents

Antineoplastic Agents

Androgens

Zoledronic Acid

Atrasentan

Endothelin A Receptor Antagonists

Endothelin Receptor Antagonists

Zoledronic Acid (Zometa)

Matthew Smith, MD, PhD

The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.

* Patients will be randomized to either receive Atrasentan alone or Atrasentan plus Zometa.
* Patients receiving Atrasentan alone will receive this drug in pill form once daily for 12 weeks. Patients will have a physical exam, blood work, and a urine sample performed once every other week during the first four weeks of medication administration. After those two initial visits, they will return to the clinic once every 4 weeks to have the same tests repeated. A bone scan and abdominal-pelvic CT Scan will be done every 12 weeks.
* After the patient has been taking Atrasentan for 12 weeks, if the disease has not progressed, they will begin combination treatment of Atrasentan and Zometa.
* Patients receiving Atrasentan plus Zometa, receive Zometa intravenously and then immediately start Atrasentan orally once daily as long as they remain on the study. Patients will return to the clinic twice over the first 4 weeks (once every other week) to have a physical exam, blood work and urine test performed. After these two initial visits, they will return to the clinic once every 4 weeks to have the tests repeated and to receive another treatment of zometa. A bone scan and an abdominal-pelvic CT Scan will be done once every 12 weeks.
* Patients participation in this study will last as long as the disease does not progress and they are not experiencing any serious side effects.

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Abbott

Massachusetts General Hospital

Matthew R. Smith, MD, PhD

Hormones

Darryl Sleep, M.D.

This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).

Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gary Gordon, MD

The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.

A Long Term Safety Study With Atrasentan

A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan

Gary Gordon, M.D.

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone	NCT00181558	Prostate Cancer Adenocarcinoma ...	Atrasentan Zoledronic Acid...	18 Years -	Massachusetts General Hospital
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer	NCT00036543	Prostate Cancer	Atrasentan	19 Years -	Abbott
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure	NCT00038662	Prostatic Neopl...	Atrasentan	19 Years -	Abbott
A Long Term Safety Study With Atrasentan	NCT00127478	Prostate Cancer Adenocarcinoma	Atrasentan	18 Years -	Abbott
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer	NCT00036556	Prostatic Neopl...	Atrasentan	19 Years -	Abbott

Spots Global Cancer Trial Database for atrasentan

Every month we try and update this database with for atrasentan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for atrasentan

Every month we try and update this database with for atrasentan cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for atrasentan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.